NMPA’s CDE Reports 4,900 Clinical Trial Filings for Innovative Drugs in 2024
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a Drug Technology Transfer Agreement with...
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) this week...
UK-based ADVANZ PHARMA announced the acquisition of commercial rights to testoviron from German giant Bayer...
Hangzhou-based Medtide Inc., a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides,...
Shanghai Innogen Pharmaceutical Technology Co., Ltd recently had its patent for efsubaglutide alfa (brand name:...
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II...
German giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the...
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that it has received clinical...
US-based health care firm Abbott (NYSE: ABT) this week entered into a partnership with the...
France major Sanofi (NASDAQ: SNY) this week signed a Memorandum of Understanding (MoU) with the...
Beijing-based Platinum Life Biotech’s Ruibosheng (amimestrocel) has been first prescribed in China, following conditional marketing...
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced that the multi-center, 24-week Phase IIb...
Sino-US firm Eccogene Inc., a partner of UK major AstraZeneca (AZ, NASDAQ: AZN), announced the...
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming announced the first patient dosing...
US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the...
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd.’s (HKG: 2196, SHA: 600196) in-house developed Category 1 drug...
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the prescription of its Category 1...
China’s Center for Drug Evaluation (CDE) website indicates that US giant Merck, Sharp & Dohme’s...
Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of...